

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 3

Please add the following new claims:

⁷ ~~129~~. (New) The antibody of claim ~~110~~⁶, or functional fragment thereof, comprising a V_H CDR1 referenced as SEQ ID NO:48.

⁸ ~~130~~. (New) The antibody of claim ~~129~~⁷, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁹ ~~131~~. (New) The antibody of claim ~~110~~⁶, or functional fragment thereof, comprising a V_H CDR1 referenced as SEQ ID NO:50.

E3 ¹⁰ ~~132~~. (New) The antibody of claim ~~131~~⁹, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

¹¹ ~~133~~. (New) The antibody of claim ~~110~~⁶, or functional fragment thereof, comprising a V_H CDR1 referenced as SEQ ID NO:52.

¹² ~~134~~. (New) The antibody of claim ~~133~~¹¹, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

¹³ ~~135~~. (New) The antibody of claim ~~110~~⁶, or functional fragment thereof, comprising a V_H CDR2 referenced as SEQ ID NO:54.

138

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 4

¹⁴~~136~~. (New) The antibody of claim ¹³~~135~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

¹⁵~~137~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR2 referenced as SEQ ID NO:56.

¹⁶~~138~~. (New) The antibody of claim ¹⁵~~137~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

E3 ¹⁷~~139~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR2 referenced as SEQ ID NO:58.

¹⁸~~140~~. (New) The antibody of claim ¹⁷~~139~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

¹⁹~~141~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:60.

²⁰~~142~~. (New) The antibody of claim ¹⁹~~141~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

139

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 5

²¹~~143~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:62.

²²~~144~~. (New) The antibody of claim ²¹~~143~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

²³~~145~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:64.

E3 ²⁴~~146~~. (New) The antibody of claim ²³~~145~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

²⁵~~147~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:66.

²⁶~~148~~. (New) The antibody of claim ²⁵~~147~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

²⁷~~149~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:68.

140

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 6

²⁸~~150~~. (New) The antibody of claim ²⁷~~149~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

²⁹~~151~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:70.

³⁰~~152~~. (New) The antibody of claim ²⁹~~151~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

E3 ³¹~~153~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:72.

³²~~154~~. (New) The antibody of claim ³¹~~153~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

³³~~155~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:74.

³⁴~~156~~. (New) The antibody of claim ³³~~155~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

141

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 7

³⁵~~157~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:76.

³⁶~~158~~. (New) The antibody of claim ³⁵~~157~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

³⁷~~159~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:78.

E3 ³⁸~~160~~. (New) The antibody of claim ³⁷~~159~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

³⁹~~161~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:80.

⁴⁰~~162~~. (New) The antibody of claim ³⁹~~161~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁴¹~~163~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:94.

142

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 8

⁴²~~164~~. (New) The antibody of claim ⁴¹~~163~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁴³~~165~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:96.

⁴⁴~~166~~. (New) The antibody of claim ⁴³~~165~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

E3 ⁴⁵~~167~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:98.

⁴⁶~~168~~. (New) The antibody of claim ⁴⁵~~167~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁴⁷~~169~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_H CDR3 referenced as SEQ ID NO:100.

⁴⁸~~170~~. (New) The antibody of claim ⁴⁷~~169~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

143

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 9

⁴⁹
~~171~~. (New) The antibody of claim ⁶~~170~~, or functional fragment thereof, comprising a V_L CDR1 referenced as SEQ ID NO:82.

⁵⁰
~~172~~. (New) The antibody of claim ⁴⁹~~171~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

E3
⁵¹
~~173~~. (New) The antibody of claim ⁶~~170~~, or functional fragment thereof, comprising a V_L CDR2 referenced as SEQ ID NO:84.

⁵²
~~174~~. (New) The antibody of claim ⁵¹~~173~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁵³
~~175~~. (New) The antibody of claim ⁶~~170~~, or functional fragment thereof, comprising a V_L CDR3 referenced as SEQ ID NO:86.

⁵⁴
~~176~~. (New) The antibody of claim ⁵³~~175~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁵⁵
~~177~~. (New) The antibody of claim ⁶~~170~~, or functional fragment thereof, comprising a V_L CDR3 referenced as SEQ ID NO:88.

144

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 10

⁵⁶
~~178~~. (New) The antibody of claim ⁵⁵~~177~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁵⁷
~~179~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_L CDR3 referenced as SEQ ID NO:90.

⁵⁸
~~180~~. (New) The antibody of claim ⁵⁷~~179~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁵⁹
~~181~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising a V_L CDR3 referenced as SEQ ID NO:92.

⁶⁰
~~182~~. (New) The antibody of claim ⁵⁹~~181~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁶¹
~~183~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR1 referenced as SEQ ID NO:82 and V_H CDR3 referenced as SEQ ID NO:68.

⁶²
~~184~~. (New) The antibody of claim ⁶¹~~183~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

145

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 11

⁶³
~~185~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR1 referenced as SEQ ID NO:82, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:68.

⁶⁴
~~186~~. (New) The antibody of claim ⁶³~~185~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

E3 ⁶⁵
~~187~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR1 referenced as SEQ ID NO:82, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:72.

⁶⁶
~~188~~. (New) The antibody of claim ⁶⁵~~187~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁶⁷
~~189~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR1 referenced as SEQ ID NO:82, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:70.

⁶⁸
~~190~~. (New) The antibody of claim ⁶⁷~~189~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁶⁹
~~191~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR1

146

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 12

referenced as SEQ ID NO:82 and V_H CDR3 referenced as SEQ ID NO:72.

⁷⁰
~~192~~. (New) The antibody of claim ⁶⁹~~191~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁷¹
~~193~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:86, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:68.

E3 ⁷²
~~194~~. (New) The antibody of claim ⁷¹~~193~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁷³
~~195~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:94.

⁷⁴
~~196~~. (New) The antibody of claim ⁷³~~195~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁷⁵
~~197~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90 and V_H CDR3 referenced as SEQ ID NO:68.

147

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 13

⁷⁶
~~198~~. (New) The antibody of claim ⁷⁵~~197~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁷⁷
~~199~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:68.

E3 ⁷⁸
~~200~~. (New) The antibody of claim ⁷⁷~~199~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁷⁹
~~201~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR1, referenced as SEQ ID NO:82, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:94.

⁸⁰
~~202~~. (New) The antibody of claim ⁷⁹~~201~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁸¹
~~203~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:96.

148

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 14

⁸²
~~204~~. (New) The antibody of claim ⁸¹~~203~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁸³
~~205~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90 and V_H CDR3 referenced as SEQ ID NO:94.

E3 ⁸⁴
~~206~~. (New) The antibody of claim ⁸³~~205~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁸⁵
~~207~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90 and V_H CDR3 referenced as SEQ ID NO:98.

⁸⁶
~~208~~. (New) The antibody of claim ⁸⁵~~207~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁸⁷
~~209~~. (New) The antibody of claim ⁶~~110~~, or functional fragment thereof, comprising the combination of CDRs V_L CDR3 referenced as SEQ ID NO:90, V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:100.

149

E

Inventor: William D. Huse
Serial No.: 09/016,061
Filed: January 30, 1998
Page 15

⁸⁸
~~210~~. (New) The antibody of claim ⁸⁷~~209~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

E3 ⁸⁹
~~211~~. (New) A grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$, or a functional fragment thereof, comprising one or more CDRs having at least one amino acid substitution in one or more CDRs of the heavy chain variable region polypeptide referenced as SEQ ID NO:6 or the light chain variable region polypeptide referenced as SEQ ID NO:8, said antibody or functional fragment thereof having increased integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity relative to parental antibody comprising a heavy chain variable region polypeptide referenced as SEQ ID NO:6 and a light chain variable region amino acid sequence referenced as SEQ ID NO:8.

⁹⁰
~~212~~. (New) The grafted antibody of claim ⁸⁹~~211~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

⁹¹
~~213~~. (New) The grafted antibody of claim ⁸⁹~~211~~, wherein said grafted antibody comprises at least one amino acid substitution in two or more of said CDRs.

⁹⁴
~~214~~. (New) The grafted antibody of claim ⁸⁹~~211~~, wherein at least one of said CDRs has two or more amino acid substitutions.

158

E